US 11,872,276 B2
Zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition
Claude Roth, Paris (FR); Etienne Simon-Loriere, Paris (FR); Anavaj Sakuntabhai, Paris (FR); and Felix Delgado, Bogota (CO)
Assigned to INSTITUT PASTEUR, Paris (FR); and UNIVERSIDAD EL BOSQUE, Bogota (CO)
Filed by INSTITUT PASTEUR, Paris (FR); and UNIVERSIDAD EL BOSQUE, Bogota (CO)
Filed on Mar. 14, 2022, as Appl. No. 17/694,440.
Application 17/694,440 is a continuation of application No. 16/762,849, granted, now 11,305,003, previously published as PCT/EP2018/080677, filed on Nov. 8, 2018.
Claims priority of application No. 17306553 (EP), filed on Nov. 9, 2017.
Prior Publication US 2022/0233678 A1, Jul. 28, 2022
Int. Cl. A61K 39/00 (2006.01); A61K 9/00 (2006.01); A61K 39/12 (2006.01); A61K 39/295 (2006.01); A61P 31/14 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01)
CPC A61K 39/12 (2013.01) [A61K 9/0029 (2013.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); C12N 2770/24122 (2013.01); C12N 2770/24134 (2013.01)] 16 Claims
 
1. A pharmaceutical composition comprising polynucleotide encoding a chimeric polyepitope an adjuvant and/or a pharmaceutically acceptable vehicle, wherein said chimeric polyepitope comprises:
(i) at least the following T-cell epitopes of (a) and (b), or (ii) at least the following T-cell epitopes of (a) and (c), or (iii) at least the following T-cell epitopes of (b) and (c):
(a) a T-cell epitope of the non-structural (NS) NS1 protein of a Zika virus (ZIKV) comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 10-12, 14, 15, 17-19, 23, 24 and 78-83,
(b) a T-cell epitope of the NS3 protein of a ZIKV comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 28, 29, 31, 33-35, 84 and 85,
(c) a T-cell epitope of the NS5 protein of a ZIKV comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 46, 48-50, 52-55, 57-60, 62, 64, 67, 69, 72, 73 and 86-91,
or a T-cell epitope variant thereof, which differs from the original amino acid sequence of the T-cell epitope of (a), (b) or (c) by point mutation of one or more amino acid residues and which has at least 90% sequence identity or more than 95% sequence identity or 99% sequence identity with said original sequence.